TG Therapeutics rose 9.5% after phase I data showed subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated. The results are supportive for the product profile and may improve confidence in the company’s formulation strategy, though this is still early-stage clinical data. The move is likely stock-specific rather than sector-wide.
TG Therapeutics rose 9.5% after phase I data showed subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated. The results are supportive for the product profile and may improve confidence in the company’s formulation strategy, though this is still early-stage clinical data. The move is likely stock-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
